FAQs
Q1. What is VITAGLUCIDE (Tirzepatide)?
VITAGLUCIDE is a first-in-class dual GIP and GLP-1 receptor agonist used for the treatment of type 2 diabetes and weight management. It mimics the body's natural incretin hormones to improve glycemic control and promote weight loss.
Q2. How does VITAGLUCIDE work?
It works by activating both GIP and GLP-1 receptors, which enhances insulin secretion in a glucose-dependent manner, suppresses glucagon production, slows gastric emptying, and reduces appetite through central nervous system effects.
Q3. What are the key benefits of VITAGLUCIDE?
VITAGLUCIDE offers superior blood sugar control, significant weight loss (up to 15% of body weight), cardiovascular protection by reducing MACE risk, and improvement in metabolic health markers.
Q4. What is the recommended dosage?
The recommended titration schedule starts with 2.5mg once weekly for 4 weeks, then escalates to 5mg/week, and can be further increased to 10mg or 15mg/week as tolerated, with medical supervision for doses above 10mg/week.
Q5. How is VITAGLUCIDE administered?
It is administered via subcutaneous (SC) or intramuscular (IM) injection once weekly.
Q6. How should VITAGLUCIDE be stored?
Before reconstitution, store at room temperature (≤25°C) protected from heat and light. After reconstitution, refrigerate at 2–8°C and use within 7 days. Do not freeze or expose to direct sunlight.
Q7. What are the common side effects?
Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These are typically mild to moderate and decrease over time with dose titration.
Q8. Who should avoid VITAGLUCIDE?
VITAGLUCIDE should be avoided by individuals with a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or known hypersensitivity to tirzepatide or any excipients.
Q9. Can VITAGLUCIDE be used with other medications?
Caution is advised when used with insulin or sulfonylureas due to increased risk of hypoglycemia. Dose adjustments and monitoring may be required. Delayed gastric emptying may affect the absorption of oral medications.
Q10. How does VITAGLUCIDE compare to GLYCOTIDE (Semaglutide)?
While both are effective, VITAGLUCIDE offers dual GIP and GLP-1 receptor activation compared to GLYCOTIDE's single GLP-1 receptor activation. This dual mechanism provides more aggressive glucose control and faster weight loss, though it may require closer medical supervision during dose escalation. The choice depends on individual patient goals and tolerability.
Q11. Does VITAGLUCIDE have cardiovascular benefits?
Yes, VITAGLUCIDE has demonstrated efficacy in reducing the risk of major adverse cardiovascular events (MACE), including stroke, heart attack, and cardiovascular mortality in adults with type 2 diabetes and established heart disease.
Q12. Is VITAGLUCIDE suitable for weight loss without diabetes?
VITAGLUCIDE is primarily indicated for type 2 diabetes management but has shown significant weight loss benefits. Use for weight loss without diabetes should be under strict medical supervision and as part of a comprehensive weight management plan.
Disclaimer
- Product images are representational; actual packaging may vary.
- Consult a healthcare provider before use—not for self-administration without supervision.
- Store as directed to prevent efficacy loss.